Epigenetic editors enter clinical trials

A new class of medicines that control the activity of individual genes without permanent genetic changes could transform the treatment of numerous diseases, from viral infections to neurological disorders. The first human trial of a therapeutic based on an ‘epigenetic editor’ began earlier this year, with a string of others due to start in the coming months.